Thursday 7 May, 2026
Introduction/Objectives: Metabolic syndrome (MetS) is a cluster of metabolic disorders including obesity, dyslipidemia, hypertension, and insulin resistance [1]. Type 2…
Read moreAbstracts
Using DeepNLME to identify promising biomarkers with an application to disease progression modelling of Alzheimer’s disease
Thursday 7 May, 2026
Introduction: Disease modeling (DM) offers a quantitative framework to characterize and predict disease progression in Alzheimer’s disease, supporting treatment evaluation…
Read moreA Population Pharmacokinetic Framework for Adalimumab TDM in Crohn’s Disease
Thursday 7 May, 2026
Introduction: Therapeutic drug monitoring (TDM) of adalimumab is used in Crohn’s disease management due to high interindividual variability in drug…
Read moreA semi-mechanistic model for tumor regression effects of IL-2 receptor-targeted nanocarrires modulating Treg activity
Thursday 7 May, 2026
Objectives Targeting regulatory T cells (Tregs) is a promising approach to overcome tumor-driven immunosuppression. For this purpose, P60 peptide shows…
Read moreModel-based meta-analysis of CGRP antagonists for migraine: A comprehensive evaluation of efficacy and dose-response modelling
Thursday 7 May, 2026
Objectives Migraine is a common, recurrent primary headache disorder of moderate-to-severe intensity that may be accompanied by symptoms in various…
Read moreAn Interactive Shiny Application for Machine Learning-Driven Covariate Selection in Pharmacometrics
Thursday 7 May, 2026
Introduction/Objectives: Machine learning (ML)-based approaches are efficient alternatives to stepwise covariate modeling (SCM) for covariate selection in pharmacometrics [1,2]. The…
Read morePharmacokinetic-Pharmacodynamic Modelling of Von Willebrand Factor/Factor VIII Prophylaxis in Von Willebrand Disease
Thursday 7 May, 2026
Introduction Von Willebrand Disease (VWD) is the most common inherited bleeding disorder, caused by a quantitative deficiency or qualitative dysfunction…
Read moreMODEL-INFORMED COMPARATIVE PHARMACOKINETIC AND PHARMACOLOGIC PROFILING HIGHLIGHT JAK1 SELECTIVITY OF POVORCITINIB
Thursday 7 May, 2026
Objectives: Povorcitinib (INCB054707) is a novel, orally administered, highly selective Janus kinase (JAK)1 inhibitor currently in phase 3 clinical trials…
Read moreTHE EFFECT OF COVARIATES ON TEMOZOLOMIDE EXPOSURE: A POPULATION PHARMACOKINETIC ANALYSIS APPROACH.
Thursday 7 May, 2026
Objectives Glioblastoma multiforme (GBM) is a poor prognosis cancer, with studies suggesting that only 4% of patients survive beyond five…
Read moreFinite Pharmacokinetics (FTPK) Software: A Giant Step Toward Model-Informed Drug and Generics Development (MIDGD)
Thursday 7 May, 2026
Introduction Pharmacokinetic (PK) analyses, data evaluation, and simulations assume that absorption of drugs administered orally or otherwise lasts forever since…
Read more